SYNAPS Dx CEO Frank Amato Presents at HolonIQ, New York: Addresses Importance of Accurately Detecting Causes of Dementia Including Alzheimer’s Disease

ROCKVILLE, Md.--(BUSINESS WIRE)-- SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), announces that Frank Amato, CEO and president, SDx will present at the HolonIQ New York Summit at 11 a.m. EST, September 22, 2022. Amato will participate in a fireside chat session titled Detecting AD in Dementia: How validated biomarkers will revolutionize neurodiagnostics? HolonIQ is starting a tour of 15 in-person summits from New York to Stockholm and from Singapore to Africa to expedite discussions on global access to critical climate, education and health resources.

Amato says, “AD dementia currently costs the US health system $290B a year and projections show global cases of the disease could triple by 2050. Diagnosing dementia, including AD, should no longer be subjective based upon surrogate indicators. There are validated biomarkers to help patients and their families find a definitive answer.”

With its DISCERN™ minimally invasive skin test, SDx assesses the factors directly related to the formation of synaptic connections in the brain. These indicators offer a proven association with loss of memory and cognition in people living with AD and other forms of dementia. DISCERN can distinguish between AD and other forms of dementia. It has demonstrated 95% sensitivity and 95% specificity in the diagnosis and management of AD.

Currently there are about 5.5 million Americans alone who are afflicted with AD which is the leading cause of dementia. Until the DISCERN test, the only way to accurately diagnose AD was through brain autopsy after death.

About SYNAPS Dx
SYNAPS Dx is a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD). The Company offers DISCERN™, the first highly accurate, minimally invasive test supporting a clinician’s definitive diagnosis of AD versus other forms of dementia, even in people recently diagnosed with dementia. SYNAPS Dx’s laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. Physicians and patients seeking more information can visit https://discerntest.com/. For more information on the Company, visit https://www.synapsdx.com/. Contact: info@synapsdx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220920005018/en/